The Vytorin controversy exposes shortcomings of surrogate endpoints
May 2008
The Vytorin controversy exposes shortcomings of surrogate endpoints.
Drugs are all too often approved and used due to their ability to change surrogate endpoints...blood pressure, lipids, serum glucose, etc.
The "ENHANCE" trial is a good reminder that these endpoints are not always accurate indicators of overall outcomes.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote